AI Summary
Thinking
Thinking
We reviewed 669 live results for skyrizi risankizumab sdn bhd and narrowed them down to the 3 options that look most worth comparing first.
The options are Skyrizi (risankizumab) Sdn Bhd, Skyrizi (risankizumab) and Skyrizi (risankizumab) 150mg.
Source: AbbVie Malaysia
Description
The Malaysian-market specific supply of Skyrizi, indicated for moderate-to-severe plaque psoriasis and related conditions. It is provided through hospital-based clinical channels and specialized pharmacies.
Best for
Malaysian medical services, psoriasis treatment and rheumatology care
Rate this product
Source: AbbVie Pharmaceuticals (Thailand) Ltd.
Description
Skyrizi (risankizumab) is a prescription biological medication used to treat adults with moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. As an IL-23 inhibitor, it targets the p19 subunit to manage chronic inflammation and is administered via subcutaneous injection, typically requiring a maintenance dose every 12 weeks after initial loading.
Best for
plaque psoriasis patients, psoriatic arthritis management, Crohn's disease treatment and long-term biologic therapy
Rate this product
Source: AbbVie Singapore
Description
Prescription biologic for the treatment of plaque psoriasis and psoriatic arthritis. The Singapore hub serves as a key regional reference for medical documentation and treatment guidelines for risankizumab therapies in Southeast Asia.
Best for
regional medical reference, Singapore-based patients and biologic therapy information
Rate this product
| Compare | #1Skyrizi (risankizumab) Sdn Bhd | #2Skyrizi (risankizumab) | #3Skyrizi (risankizumab) 150mg |
|---|---|---|---|
| Source | AbbVie Malaysia | AbbVie Pharmaceuticals (Thailand) Ltd. | AbbVie Singapore |
| Description | The Malaysian-market specific supply of Skyrizi, indicated for moderate-to-severe plaque psoriasis and related conditions. It is provided through hospital-based clinical channels and specialized pharmacies. | Skyrizi (risankizumab) is a prescription biological medication used to treat adults with moderate-to-severe plaque psoriasis, psoriatic arthritis, and Crohn's disease. As an IL-23 inhibitor, it targets the p19 subunit to manage chronic inflammation and is administered via subcutaneous injection, typically requiring a maintenance dose every 12 weeks after initial loading. | Prescription biologic for the treatment of plaque psoriasis and psoriatic arthritis. The Singapore hub serves as a key regional reference for medical documentation and treatment guidelines for risankizumab therapies in Southeast Asia. |
| Best for | Malaysian medical services, psoriasis treatment and rheumatology care | plaque psoriasis patients, psoriatic arthritis management, Crohn's disease treatment and long-term biologic therapy | regional medical reference, Singapore-based patients and biologic therapy information |
| Action | AbbVie Malaysia | AbbVie Pharmaceuticals (Thailand) Ltd. | AbbVie Singapore |
| Rate this product |
"Skyrizi (risankizumab) Sdn Bhd from AbbVie Malaysia."
TopFind picked this because Ensures access to the authentic IL-23 inhibitor within Malaysia's pharmaceutical regulatory framework.
Note: TopFind AI compiles product and service information for general comparison purposes only.